Astrazeneca (AZN) Expected to Announce Quarterly Earnings on Friday

Key Points

• AstraZeneca is expected to report Q3 2026 earnings on October 30. Analysts forecast EPS of $2.59 and revenue of $16.02 billion; management’s growth outlook and quarterly execution will be key catalysts.
• The company’s latest quarter exceeded EPS expectations, with $2.63 reported versus $2.50 expected, while revenue increased 6.4% year over year to $15.38 billion.
• Pipeline developments are mixed but generally supportive. Ultomiris gained a new FDA indication, sunvozertinib launched for a targeted lung-cancer treatment, and TEZSPIRE delivered positive Phase III results, though a Wainua trial miss remains a risk.

Astrazeneca (NYSE:AZN - Get Free Report) will likely be posting its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect the company to post earnings of $2.59 per share and revenue of $16.02 billion for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, October 30, 2026 at 10:30 AM ET.

Astrazeneca (NYSE:AZN - Get Free Report) last released its earnings results on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.13. The company had revenue of $15.38 billion for the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. The firm's quarterly revenue was up 6.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.17 EPS. On average, analysts expect Astrazeneca to post $9.38 EPS for the current fiscal year and $10.54 EPS for the next fiscal year.

Astrazeneca Stock Performance

NYSE:AZN opened at $172.64 on Friday. Astrazeneca has a 52 week low of $153.41 and a 52 week high of $212.71. The company has a fifty day simple moving average of $162.92 and a two-hundred day simple moving average of $175.19. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. The company has a market cap of $267.75 billion, a price-to-earnings ratio of 17.35, a price-to-earnings-growth ratio of 1.42 and a beta of 0.27.

Analyst Upgrades and Downgrades

Several research analysts recently commented on AZN shares. Zacks Research raised Astrazeneca from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 13th. HSBC cut shares of Astrazeneca from a "buy" rating to a "hold" rating in a report on Monday, July 13th. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Wall Street Zen cut Astrazeneca from a "buy" rating to a "hold" rating in a research report on Sunday, October 11th. Finally, Weiss Ratings downgraded Astrazeneca from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, July 28th. Fifteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $206.67.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Ultomiris gains a fifth U.S. indication. The FDA granted accelerated approval for Ultomiris (ravulizumab) to treat adults with IgA nephropathy, making it the first C5 inhibitor approved for the rare kidney disease and expanding the drug’s revenue potential. AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy
• Positive Sentiment: New targeted lung-cancer drug launches in the United States. AstraZeneca launched sunvozertinib for patients with EGFR exon 20 insertion-mutated non-small cell lung cancer following accelerated FDA approval. The launch adds a potential growth product in a specialized oncology market. AstraZeneca launches sunvozertinib for EGFR exon 20 NSCLC
• Positive Sentiment: TEZSPIRE posts encouraging Phase III results. AstraZeneca and Amgen reported statistically significant and sustained efficacy for TEZSPIRE in eosinophilic esophagitis. A successful regulatory submission could expand the drug beyond its current indications and broaden its commercial opportunity. AstraZeneca Reports Positive Phase III Results in Eosinophilic Esophagitis
• Neutral Sentiment: Investors are awaiting quarterly results. AstraZeneca is scheduled to report third-quarter earnings next week. Management has reaffirmed its outlook for mid- to high-single-digit revenue growth and low-double-digit core EPS growth, making execution and guidance key near-term catalysts. Is AstraZeneca Stock Cheap?
• Negative Sentiment: Recent pipeline setbacks remain a risk. AstraZeneca’s Wainua trial miss tempers the otherwise positive pipeline news and highlights the uncertainty surrounding research and development investments. Can AstraZeneca Shrug Off Its Wainua Trial Miss?

About Astrazeneca

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca's portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.